References
- Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915–28.
- Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 2009;10:923–36.
- Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene 2009;28:3009–21.
- Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236–42.
- Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, . IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006;107:669–78.
- Yin S, Girnita A, Stromberg T, Khan Z, Andersson S, Zheng H, . Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 2010;12:19–27.
- Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, . Tumor cavitation: Impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009;27:404–10.
- Hatzidaki D, Agelaki S, Mavroudis D, Vlachonikolis I, Alegakis A, Georgoulias V; Lung Cancer Group of the Hellenic Oncology Research Group. A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006;1:49–55.
- Bedano PM, Hanna N. Salvage therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006;6:582–7.
- Karp DD, Paz-Ares L, Novello S, Haluska P, Garland L, Cardenal F, . High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. ASCO Meeting Abstracts 2008;15 (Suppl):8015.
- Kobayashi M, Okamoto K, Nakatani H, Okabayashi T, Namikawa T, Ichikawa K, . Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: Report of a case. Surg Today 2006;36:727–32.
- Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: Role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006;26:481–95.
- Van den Abbeele AD. The lessons of GIST-PET and PET/CT: A new paradigm for imaging. Oncologist 2008;13:8–13.